The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | Evaluating the efficacy of CAR T-cell therapies
Follow-up care for cancer patients is necessary to evaluate the effectiveness of the treatment they receive. Here, Arnon Nagler, MD, from Chaim Sheba Medical Center, Tel-Aviv, Israel, describes the numerous predictive factors that are currently being used to evaluate the response towards CAR T-cell therapy. This video was recorded at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
